 |
|
||
|
|
||
|
|
|||
Strategic alliances
Max Planck Institute of Biochemistry The Max Planck Institute of Biochemistry is a research institute of the Max Planck Society located in Martinsried, a suburb of Munich. The Max Planck Institute of Biochemistry, founded 1912 as a Kaiser Wilhelm Institute, was relocated from Berlin in 1945 to Tübingen and moved once more in 1956 to Munich. During this time from 1933 on Adolf Butenandt was director of the institute. The institute in Munich was founded 1973 by the merger of three former independent institutes, the Max Planck Institute of Biochemistry, the Max Planck Institute of Protein and Leather Research, founded 1954 in Regensburg, and the Max Planck Institute of Cell Chemistry, founded 1956 in Munich. 
Semmelweis University Semmelweis University, university for medicine and health-related disciplines, located in Budapest, Hungary, named after the Hungarian physician Ignaz Semmelweis. Semmelweis University has a more than 230-year old tradition of academic excellence and commitment to the education of physicians. Among Semmelweis alumni are Nobel-laureates, world renowned researchers and clinicians. Current enrolment at the Faculty of Medicine is 2907 students, at the Faculty of Dentistry 500, and at the Faculty of Pharmacy 604. Four percent of all medical students are foreign citizens studying in Hungarian. 
KPS Biotechnology and Healthcare Ltd KPS is a private spin off company of the Semmelweis University founded by two biomedical researchers Richard Schwab and Istvan Petak in 2003. KPS develops cell and gene therapies, molecular diagnostic methods for individualized therapy of molecular targeted drugs, and provides bioassays for drug discovery focusing on cancer and inflammatory diseases. KPS was the first company which received government funding for cell and gene therapy research in 2004. In 2005 KPS became the part of the Szentágothai Knowledge Center, a consortium led by the University. KPS started to provide also private health care services in 2005. Clinical facilities are located at one of Budapest busiest private clinics: Kelen Hospital. 
Kinaxo Biotechnologies GmbH Kinaxo Biotechnologies GmbH is a dedicated service company spun out of the Max-Planck Institute of Biochemistry in Martinsried, Germany. We support pharmaceutical and biotechnology companies in the selection and optimization of targeted kinase drug candidates. Kinaxo has a secure IP position with an exclusive worldwide license to the KinaTor?-patents for its fee-for-service activities. The KinaTor technology was developed and optimized over several years by its founders Dr. Henrik Daub and Dr. Axel Ullrich. Additional founding shareholders are Dr. Hellmut Kirchner, Axel Leimer and Dr. Andreas Jenne, as well as BioM AG and the Max Planck Society. 
Proteros biostructures GmbH Proteros is Europe´s most experienced and largest biotechnology company in the field of X-ray protein structure analysis and a leading service partner for fully integrated lead discovery. Successful in business since 1998, Proteros collaborates with more than 80 international pharma, biotech and agricultural companies. Focusing on services, Proteros provides protein crystallography, access to various complementary compound libraries in conjunction with unique assay technologies and medicinal chemistry capabilities to generate novel lead compounds for therapeutically relevant targets. Proteros is privately-owned and was co-founded by Nobel Prize winner Prof. Dr. Robert Huber, one of the pioneers of structural and functional analysis of proteins.
|
|
 |
|